MYLOTARG
Drug
PFIZER INC.
Total Payments
$21.8M
Transactions
6,212
Doctors
2,270
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.3M | 13 | 1 |
| 2023 | $976,344 | 27 | 17 |
| 2022 | $2.0M | 39 | 21 |
| 2021 | $3.2M | 33 | 11 |
| 2020 | $4.6M | 76 | 16 |
| 2019 | $4.5M | 1,414 | 791 |
| 2018 | $1.1M | 3,508 | 1,644 |
| 2017 | $4.3M | 1,102 | 730 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $21.3M | 170 | 97.5% |
| Consulting Fee | $336,905 | 95 | 1.5% |
| Food and Beverage | $72,027 | 5,217 | 0.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $54,410 | 39 | 0.2% |
| Travel and Lodging | $46,461 | 115 | 0.2% |
| Honoraria | $16,428 | 3 | 0.1% |
| Education | $10,165 | 573 | 0.0% |
Payments by Type
Research
$21.3M
170 transactions
General
$536,396
6,042 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CHILDRENS HOSPITAL OF PHILADELPHIA COG AGREEMENT 44ML0531 | PFIZER INC. | $4.1M | 0 |
| PHASE 12 STUDY OF SINGLE OR FRACTIONEDDOSE GEMTUZUMAB OZOGAMICIN IN COMBINATION WITH GCSF CLADRIBINE CYATARABINE AND MITOXANTRONE GCLAM FOR THE TREATMENT OF PREVIOUSLY UNTREATED ADULT ACUTE MYELOID LEUKEMIA | PFIZER INC. | $2.3M | 0 |
| FULL_ A PHASE 2 STUDY OF INOTUZUMAB OZOGAMICIN IN CHILDREN AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY CD22 B-ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) | PFIZER INC. | $2.0M | 0 |
| PHASE 11B TRIAL OF TALAZOPARIB AND GEMTUZUMAB OZOGAMICIN IN ADULT PATIENTS WITH RELAPSED ANDOR REFRACTORY ACUTE MYELOID LEUKEMIA | PFIZER INC. | $1.5M | 0 |
| FRACTIONATED GEMTUZUMAB OZOGAMICIN TO ERADICATE MEASURABLE RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA PATIENTS GO FOR MRD | PFIZER INC. | $1.1M | 0 |
| PHASE IB STUDY OF THE SAFETY AND EFFICACY OF GEMTUZUMAB OZOGAMICIN AND VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA OR WITH TREATMENTNAIVE AML WHO ARE NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY | PFIZER INC. | $1.1M | 0 |
| PHASE I STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF GEMTUZUMAB OZOGAMICINMYLOTARG IN COMBINATION WITH CYTARABINE ANTHRACYCLINE AND MIDOSTAURIN INDUCTION FOR PATIENTS WITH NEWLY DIAGNOSED FLT3 POSITIVE ACUTE MYELOID LEUKEMIA AML | PFIZER INC. | $1.0M | 0 |
| FRACTIONATED GEMTUZUMAB OZOGAMICIN FOLLOWED BY NONENGRAFTMENT DONOR LEUKOCYTE INFUSIONS FOR RELAPSEDREFRACTORY ACUTE MYELOID LEUKEMIA | PFIZER INC. | $1.0M | 0 |
| WS900799 PHASE II STUDY OF TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH ATRA ARSENIC TRIOXIDE AND GEMTUZUMAB OZOGAMICIN | PFIZER INC. | $932,949 | 0 |
| AN OPENLABEL PHASE IBII MULTIARM STUDY OF OX40 MONOCLONAL ANTIBODY MAB 41BB MAB PDL1 MAB HEDGEHOG INHIBITOR CD33 MAB AND AZACYTIDINE AS SINGLEAGENTS ANDOR COMBINATIONS FOR THE TREATMENT OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AML | PFIZER INC. | $895,957 | 0 |
| A PHASE II STUDY OF CLADRIBINE CYTARABINE AND GRANULOCYTECOLONY STIMULATING FACTOR WITH FRACTIONATED GEMTUZUMAB OZOGAMICIN CLAGGO FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA | PFIZER INC. | $707,052 | 0 |
| A NONINTERVENTIONAL POSTAUTHORISATION SAFETY STUDY TO CHARACTERIZE TOXICITY FOLLOWING GEMTUZUMAB OZOGAMICIN TREATMENT AND HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA | PFIZER INC. | $547,425 | 0 |
| FULL VYXEOS PLUS MYLOTARG FOR RELAPSED ACUTE MYELOGENOUS LEUKEMIA | PFIZER INC. | $542,656 | 0 |
| WI237938 PHASE I STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF GEMTUZUMAB OZOGAMICINMYLOTARG IN COMBINATION WITH CYTARABINE ANTHRACYCLINE AND MIDOSTAURIN INDUCTION FOR PATIENTS WITH NEWLY DIAGNOSED FLT3 POSITIVE ACUTE MYELOID LEUKEMIA AML | PFIZER INC. | $507,188 | 0 |
| PHASE II STUDY OF TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH ATRA ARSENIC TRIOXIDE AND GEMTUZUMAB OZOGAMICIN | PFIZER INC. | $494,828 | 0 |
| A SINGLE ARM OPENLABEL PHASE 4 STUDY EVALUATING QT INTERVAL PHARMACOKINETICS AND SAFETY OF GEMT | PFIZER INC. | $490,077 | 0 |
| COPY OF FULL PHASE I STUDY OF PRACINOSTAT IN COMBINATION WITH GEMTUZUMAB OZOGAMICIN IN PATIENTS WITH RELAPSED REFRACTORY ACUTE MYELOID LEUKEMIA | PFIZER INC. | $488,334 | 0 |
| DAUNORUBICIN LIPOSOME INJECTION IN COMBINATION WITH GEMTUZUMAB OZOGAMICIN IN SUBJECTS WITH AML OR 55 YEARS OF AGE WHO HAVE NOT BEEN TREATED WITH INTENSIVE CHEMOTHERAPY | PFIZER INC. | $309,458 | 0 |
| COPY OF PHASE II TRIAL OF CPX351 CYTARABINEDAUNORUBICIN LIPOSOME INJECTION ALONE AND IN COMBINATION WITH GEMTUZUMAB OZOGAMICIN IN PATIENTS WITH ACUTE MYELOID LEUKEMIA 60 YEARS OF AGE WHO HAVE NOT BEEN TREATED WITH INTENSIVE CHEMOTHERAPY | PFIZER INC. | $301,715 | 0 |
| WI234149 PHASE IB STUDY OF THE SAFETY AND EFFICACY OF GEMTUZUMAB OZOGAMICIN GO AND VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY CD33 ACUTE MYELOID LEUKEMIA BIG TEN CANCER RESEARCH CONSORTIUM BTCRCAML17113 | PFIZER INC. | $298,772 | 0 |
Top Doctors Receiving Payments for MYLOTARG — Page 91
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Hematology | Pomona, CA | $5.15 | 1 |
| , M.D | Hematology & Oncology | Aguas Buenas, PR | $5.05 | 3 |
| , M.D | Hematology & Oncology | Fort Lauderdale, FL | $3.54 | 1 |
| , MD | Hematology & Oncology | Caguas, PR | $3.49 | 2 |
| , MD | Hematology & Oncology | Caguas, PR | $3.49 | 2 |
| , MD | Hematology & Oncology | Rio Piedras, PR | $3.46 | 1 |
| , M.D | Medical Oncology | West Palm Beach, FL | $3.39 | 1 |
| , D.O | Hematology & Oncology | Orange, CA | $3.36 | 2 |
| , M.D., MBA | Hematology & Oncology | Palm Beach Gardens, FL | $2.89 | 1 |
| , M.D | Hematology & Oncology | Poplar Bluff, MO | $2.81 | 1 |
| , MD | Medical Oncology | Joliet, IL | $2.75 | 1 |
| , M.D | Hematology & Oncology | Pine Bluff, AR | $2.73 | 1 |
| , MD | Medical Oncology | Lubbock, TX | $2.64 | 1 |
| , D.O | Internal Medicine | Maywood, IL | $2.47 | 1 |
| Everett Grahn | — | Orange, CA | $2.41 | 2 |
| , MD | Hematology & Oncology | Los Angeles, CA | $2.07 | 1 |
| , MD | Hematology & Oncology | Orlando, FL | $1.70 | 1 |
| , M. D | Student in an Organized Health Care Education/Training Program | Orlando, FL | $1.70 | 1 |
| , MD | Hematology & Oncology | Worcester, MA | $1.23 | 1 |
| , MD | Hematology & Oncology | Burlington, VT | $1.23 | 1 |
| , DO | Rheumatology | Santa Barbara, CA | $0.21 | 1 |
Ad
Manufacturing Companies
- PFIZER INC. $21.8M
- WHITEHALL INTERNATIONAL INC $2,500
- Pfizer Inc. $8.36
Product Information
- Type Drug
- Total Payments $21.8M
- Total Doctors 2,270
- Transactions 6,212
About MYLOTARG
MYLOTARG is a drug associated with $21.8M in payments to 2,270 healthcare providers, recorded across 6,212 transactions in the CMS Open Payments database. The primary manufacturer is PFIZER INC..
Payment data is available from 2017 to 2024. In 2024, $1.3M was paid across 13 transactions to 1 doctors.
The most common payment nature for MYLOTARG is "Unspecified" ($21.3M, 97.5% of total).
MYLOTARG is associated with 20 research studies, including "CHILDRENS HOSPITAL OF PHILADELPHIA COG AGREEMENT 44ML0531" ($4.1M).